Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03719690
Title Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)
Acronym AIM-HN/SEQ-HN
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Kura Oncology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | GBR | ESP | DEU | BEL | AUT | AUS

Additional content available in CKB BOOST